Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($2.15), $0.90 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $2.13 million versus the consensus estimate of $2.54 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.